Effects of three blood purification methods on serum fibroblast growth factor‑23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis

Miao,Li-Ying; Zhu,Bin; He,Xiao-Zhou; Liu,Jin-Feng; Jin,Li-Na; Li,Xiu‑Rong; Xue,Li-Na; Huang,Tian; Shen,Jian‑Qin; Xing,Chang‑Ying

doi:10.3892/etm.2014.1543

2014-April Volume 7 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-April Volume 7 Issue 4

Full Size Image

Article

Effects of three blood purification methods on serum fibroblast growth factor‑23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis

Authors:
- Li-Ying Miao
- Bin Zhu
- Xiao-Zhou He
- Jin-Feng Liu
- Li-Na Jin
- Xiu‑Rong Li
- Li-Na Xue
- Tian Huang
- Jian‑Qin Shen
- Chang‑Ying Xing
View Affiliations / Copyright

Affiliations: The Blood Purification Center, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Critical Care Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Pages: 947-952
|
Published online on: February 13, 2014

https://doi.org/10.3892/etm.2014.1543
Expand metrics +

Abstract

The aim of the present study was to investigate the effects of three blood purification methods on fibroblast growth factor‑23 (FGF‑23) clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis (MHD). In addition, the correlation between serum FGF‑23 and phosphorus (Pi) levels and the clinical implications were identified. Sixty‑five MHD patients with hyperphosphatemia were randomly divided into three groups: Hemodialysis, HD (n=23); hemodiafiltration, HDF (n=21); and hemodialysis+hemoperfusion, HD+HP (n=21) groups. Serum Pi, FGF-23, blood urea nitrogen, serum creatinine and associated bio‑marker levels were measured prior to and following treatment. The expression level of serum FGF‑23 was observed to be positively correlated with Pi (r=0.45, P<0.01). The three blood purification methods that were adopted for the present study exhibited significant and effective clearance of serum Pi (P<0.05). The post-treatment serum FGF‑23 levels were significantly decreased in the HDF and HD+HP groups (P<0.05). Therefore, HDF may be an effective method for clearing serum FGF‑23 in MHD patients exhibiting hyperphosphatemia.

View Figures

View References

1	National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1): S1–S266. 2002.PubMed/NCBI
2	Vassalotti JA, Stevens LA and Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 50:169–180. 2007. View Article : Google Scholar : PubMed/NCBI
3	Stevens LA and Levey AS: Current status and future perspectives for CKD testing. Am J Kidney Dis. 53(3 Suppl 3): S17–S26. 2009. View Article : Google Scholar : PubMed/NCBI
4	Levey AS and Coresh J: Chronic kidney disease. Lancet. 379:165–180. 2012. View Article : Google Scholar
5	Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE and Go AS: The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 74:101–107. 2008. View Article : Google Scholar : PubMed/NCBI
6	James MT, Hemmelgarn BR, Wiebe N, et al; Alberta Kidney Disease Network. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet. 376:2096–2103. 2010. View Article : Google Scholar : PubMed/NCBI
7	James MT, Quan H, Tonelli M, et al; Alberta Kidney Disease Network. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 54:24–32. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hailpern SM, Melamed ML, Cohen HW and Hostetter TH: Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 18:2205–2213. 2007.
9	Miyamoto K, Ito M, Tatsumi S, Kuwahata M and Segawa H: New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol. 27:503–515. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hu P, Xuan Q, Hu B, Lu L, Wang J and Qin YH: Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. Int J Biol Sci. 8:663–671. 2012. View Article : Google Scholar : PubMed/NCBI
11	Slatopolsky E and Moe S: 50 years of research and discovery in chronic kidney disease and mineral & bone disorder: the central role of phosphate. Kidney Int Suppl. S1–S2. 2011.PubMed/NCBI
12	Shigematsu T, Nakashima Y, Ohya M, et al: The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients. Int J Nephrol Renovasc Dis. 5:81–89. 2012. View Article : Google Scholar : PubMed/NCBI
13	Gutierrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 16:2205–2215. 2005. View Article : Google Scholar : PubMed/NCBI
14	Bia M, Adey DB, Bloom RD, Chan L, Kulkarni S and Tomlanovich S: KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis. 56:189–218. 2010. View Article : Google Scholar : PubMed/NCBI
15	Noordzij M, Korevaar JC, Boeschoten EW, et al; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 46:925–932. 2005. View Article : Google Scholar : PubMed/NCBI
16	Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 4:1205–1213. 1993.PubMed/NCBI
17	Perwad F, Zhang MY, Tenenhouse HS and Portale AA: Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 293:F1577–F1583. 2007. View Article : Google Scholar : PubMed/NCBI
18	Goetz R, Nakada Y, Hu MC, et al: Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA. 107:407–412. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chen HC, Lim LM, Chang JM and Misra M: Save life and improve quality: Report from the 5th Congress of International Society for Hemodialysis. Hemodial Int. Jul 30–2013.(Epub ahead of print).
20	Urena Torres P, Friedlander G, de Vernejoul MC, Silve C and Prié D: Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 73:102–107. 2008.
21	Patrier L, Dupuy AM, Granger Vallée A, et al: FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis. J Nephrol. 26:342–349. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effects of three blood purification methods on serum fibroblast growth factor‑23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Related Articles